Lilly's schizophrenia drug may offer breakthrough

Eli Lilly has revealed that a clinical trial involving some 200 volunteers has demonstrated the effectiveness of its experimental therapy against schizophrenia. The therapy is being heralded as a potential breakthrough in the field which would steer clear of many of the harsh side effects associated with existing schizophrenia drugs. Researchers also caution, though, that work on LY2140023 is still at an early stage. Nevertheless, analysts were awed by the potential of a new lead therapy in the field. Schizophrenia drugs took in $12 billion in the U.S. last year--$18 billion worldwide.

- check out the release
- read the report from MarketWatch

Related Articles:
Researchers: New schizophrenia drugs little better than the old. Report
Lilly agrees to $690M drug settlement. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.